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Abstract
Purpose Thrombotic and embolic vascular occlusion
represents a leading cause of morbidity and mortality.
Currently available thrombectomy devices have limita-
tions, including difﬁculty removing organized thrombus
and clot fragmentation with distal embolization. A novel
mechanical thrombectomy device (MTD), designed to
remove both hard and soft thrombus without trauma to the
blood vessel, was tested in preclinical porcine models
evaluating efﬁcacy, safety, and ease of use.
Materials and Methods A total of 26 vessels in 14 pigs
underwent mechanical thrombectomy with MTD. Throm-
bectomy was performed in nine superﬁcial femoral arteries,
eight subclavian arteries, ﬁve primary branches of the
subclavian artery, lateral thoracic artery or the thyrocervi-
cal trunk, and four external carotids. Subacute organized
ﬁbrin-laden thrombus was injected into the arteries pro-
ducing vascular occlusion. The MTD was then used for
thrombectomy to restore patency and blood ﬂow.
Results Intact thrombus was retrieved from 24 of 26 of
the vessels with a single pass of the MTD, resulting in
complete restoration of patency in 21 vessels and partial
patency in 4 vessels. In 8 cases that used an early design,
the embolic material fragmented during withdrawal from
the access sheath. In 4 procedures that used an early design,
the MTD failed to deploy fully and the embolus was not
completely captured. No intraprocedural complications or
vascular damage occurred.
Conclusions The present pilot studies demonstrate basic
safety and efﬁcacy of a novel MTD with design attributes
suitable for retrieval of intact acute and organized chronic
thrombus. The device has potential intracranial and
peripheral utility.
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Introduction
Current thrombectomy devices and thrombolytic drugs do
notreliablyremovelargeorhardbloodclots,andsomedrugs
anddevicesareassociatedwithsigniﬁcantadverseoutcomes
[1–4]. Pharmacologic thrombolysis also commonly results
in longer procedure times, often with prolonged observation
required in an intensive care unit with resulting increased
procedure-related costs. It would therefore be advantageous
to have a simple mechanical device that could safely and
efﬁciently remove intact complex acute, subacute, and
chronic thrombus from any vascular bed.
We have evaluated a novel catheter-based mechanical
retriever shown in prior benchtop in vitro tests to be
capable of mechanically retracting both acute soft and hard
chronic, organized thrombus. The mechanical thrombec-
tomy device (MTD) design is intended to allow easier
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delivered through a 4F angiographic or 2.7F microcatheter
for the small branches of the subclavian artery, depending
on the target vessel. The MTD described here is based on
materials utilized for guide wires and intracranial aneurysm
coil construction is not traumatic to the vascular wall, with
minimal risk of intimal dissection or endothelial injury.
Here we report the results of a series of preclinical
studies conducted to evaluate the technical efﬁcacy,
device-related complications, and ease of device use of the
MTD in a porcine model of embolic/thrombotic arterial
occlusion.
Materials and Methods
Device Design and Description of Components
The MTD, manufactured by NexGen Medical Systems
(Reno, NV), is similar in general design to a vascular guide
wire and detachable coil. The device consists of a platinum
microcoil element for head and neck arteries, and a stain-
less steel microcoil element for peripheral blood vessels. A
hollow catheter shaft is attached to the microcoil, and
eyelets are set at discrete locations along the microcoil
(Fig. 1). A metal core wire travels through the lumen of the
catheter shaft, goes through the eyelets of the microcoils,
and attaches to the distal tip of the microcoil complex
(Fig. 1A–F). Pulling on the core wire forms a loop
(Fig. 1D–F) of a given microcoil. Microcoil loop diameters
are based on the distance between eyelets, and also on the
degree of pull on the core wire, which provides design
ﬂexibility to vary the diameter of each loop formed. The
actuated coils (those with loops) are used to capture,
encapsulate, and retrieve a blood clot or other obstruction
(Fig. 2).
When performing thrombectomy in the branches of the
subclavian or external carotid arteries, the MTD had a shaft
length of 175 cm with distal loops measuring 3.5 mm wide
by 1.0 cm long, and proximal loops measuring 5 mm 9
6 cm.Forneurothrombectomyapplications,evaluatedinthe
external carotid artery, the loops also measured 3.5 mm in
Fig. 1 Device design.
Components of the MTD are
illustrated. A The device
consists of a platinum or
stainless steel coil element
attached to a stainless steel
hypotube via a polyamide
transition tube (A, B). Within
the tubes and coil element is a
stainless steel core wire (A–F).
Near the distal tip, the core wire
exits the device and runs
alongside the coil element,
reentering the coil element at
deﬁned eyelets (C). The eyelet
portion of the coil element
forms discrete loops when the
user retracts the proximal end of
the core wire (D–F). Proximal
to the eyelet section, the coil
element is preshaped to form a
spiraled coil shape (E)
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123diameter, the outside diameter of the MTD was 0.021 in. at
the eyelet locations, and the device was designed so that it
could be inserted through a microcatheter with an internal
lumen of 0.027 in. For thrombectomy procedures in the
superﬁcial femoral arteries, the device loops measured up to
16 mm in diameter by 10 cm in length in the unrestrained
(not within the vessel) conﬁguration. In four of nine cases,
the thrombus extended from the superﬁcial femoral artery
into a smaller-diameter popliteal artery, profunda femoral
artery, or muscular perforating branch. For these cases, the
device had three tapering distal coils measuring 5, 4, and
3 mm in diameter. Thus, the MTD dimensions and speciﬁ-
cations can be varied for optimal functioning in occluded
vessels of differing diameter and length.
Principle of Operation
The MTD is inserted into a 4F angiographic catheter or
0.027-in. microcatheter positioned distal to the obstruction,
using conventional over-the-wire coaxial angiographic
technique (Fig. 2A). The device is advanced (Fig. 2B) and
then actuated to form the distal loops (Fig. 2C). These
loops act as a cap over the distal aspect of the thrombus. To
ensure retrieval of the intact clot or other obstruction, the
preshaped coils are then advanced out of the microcatheter
around the midportion of the thrombus and then the
proximal portion of the clot as the catheter is progressively
pulled back to unsheath the device (Fig. 2D). Once placed,
the core wire is further retracted to tighten the coil structure
around the obstructing thrombus (Fig. 2E). The obstructing
thrombus, now fully encapsulated within the coil element,
can be safely and completely removed without fragmen-
tation (Fig. 2F).
Animal Preparation
All studies involving experimental animals were performed
at the University of California at Davis (UCD) in full
compliance with U.S. National Institutes of Health Guide-
lines. UCD research ethics board approval was obtained in
advance of conducting any experiments involving animals.
Four- to 6-month-old Yorkshire pigs (34–46 kg body
weight) were tranquilized with a combination of ketamine
hydrochloride (20 mg/kg, i.m.) and xylazine (2 mg/kg,
i.m.) or with Telazol (4.5 mg/kg, i.m.) by qualiﬁed animal
care technologists. After endotracheal intubation, the ani-
mal was anesthetized with 2% isoﬂurane gaseous inhalent.
An intravenous line was placed for collection of blood
samples and administration of heparin (150 U/kg body
weight). Animals were transferred to the angiography suite
of the surgical research facility. Continuous physiological
monitoring of the animal was performed throughout the
angiographic procedures.
Thrombus-Embolic Model
Thrombi were produced from fresh pig blood drawn in a
previous experiment. The initial experiments were per-
formed with whole pig blood that was allowed to stand in a
glass beaker in a refrigerator for 4 days. This produced
Fig. 2 Principles of operation.
Device is passed distal to the
thrombus coils are formed
distal, within, and proximal to
the thrombus. The thrombus is
then cocooned within the MTD
and retracted from the vessel
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123both a white ﬁbrin clot and a red, more gelatinous clot. We
cut a portion of the white ﬁbrin material from the total and
embolized it into the vessel of interest. This material was
chosen to represent a hard clot, such as might be seen in a
patient with atrial ﬁbrillation. A similar thrombus model
has been described [5]. The clot size varied, depending on
the vessel to be embolized. For branches of the subclavian
or external carotid artery, hard ﬁbrin-laden clots 4 mm in
diameter by 6 mm in length were cut from the experi-
mental clot. For embolization into the superﬁcial femoral
artery and its branches, the clot was approximately 8 mm
in diameter and 5 to 10 cm long. The single clot was
delivered intact through a 10F sheath. The clot was not
mixed with contrast in order to avoid changing its consis-
tency and thus was not radiopaque. Placement and retrieval
were demonstrated by pre- and postthrombectomy angi-
ography (Fig. 3A–C) and extracted thrombus evaluated
(Fig. 3D). In all cases, the vessel was completely occluded
with thrombus before thrombectomy.
Experimental Procedure
The goal of the experiments was to evaluate this throm-
bectomy device in a number of vascular distributions,
which might be relevant to clinical practice. A total of 26
vessels in 14 pigs underwent mechanical thrombectomy by
MTD. Thrombectomy was performed in nine superﬁcial
femoral arteries, eight subclavian arteries, ﬁve primary
branches of the subclavian artery including the lateral
thoracic artery and the thyrocervical trunk, and four
external carotid arteries. Vessels measured between 3 and
9 mm in diameter.
After surgical exposure of the right common femoral
artery, a 10F femoral sheath with a nonremovable hub was
inserted using the Seldinger technique. Angiography was
performed with a Siemens Power Mobil C-Arm. Angiog-
raphy was initially performed of the artery to be studied.
including the subclavian, external carotid, and superﬁcial
femoral arteries, with a 9F intra-arterial guiding catheter.
Selective catheterization of these vessels or their branches
was followed by injection of the thrombus to produce
selective focal occlusion of the vessel, which was con-
ﬁrmed with subsequent angiography. A 4F angled glide
catheter (Cook, Bloomington, IN) without or with a 2.7F
Fastracker or Infusion microcatheter (Boston Scientiﬁc,
Boston, MA) with a 0.014-in. micro-guide wire (Boston
Scientiﬁc) were used to attain position distal to the
thrombus under ﬂuoroscopy with road mapping capability.
After removal of the guide wire, the MTD was passed
through the catheter and positioned so that the tip was
Fig. 3 Angiography during
porcine femoral thrombectomy.
A Prethrombectomy
angiography demonstrates
complete femoral artery
occlusion. B MTD being
deployed at site of thrombotic
occlusion. C Postthrombectomy
angiography demonstrates
complete revascularization,
restoration of vascular patency,
after a single application of the
MTD. D MTD with thrombus
within coil network after
thrombectomy
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123distal to the intra-arterial embolic occlusion. Angiographic
visualization was used to conﬁrm the position of the device
in relation to the embolus. The distal coils of the MTD
were activated to form a cap on the distal surface of the
embolus, after which the catheter was pulled back so that
more proximal coils of the device were exposed to sur-
round the midportion of the embolus. After pulling the
catheter proximal to the embolus, more coils were formed
to abut the proximal aspect of the thrombus. The distal and
proximal coils of the device were drawn together by the
pull string/pull wire to enmesh the embolus securely at
both its distal and proximal aspects. The embolus was then
retracted toward the guide catheter and removed from the
blood vessel (Fig. 2). A photograph was made of the
extracted clot and device coil mesh. Angiography was
repeated after a single sweep with the thrombectomy
device, and restoration of ﬂow was evaluated to determine
the degree of recanalization of the previously occluded
blood vessel (Fig. 3). Angiographic data were recorded on
tape and archived for subsequent analysis.
In three experiments, embolized blood vessels were
surgically removed after the thrombectomy procedure for
histopathologic assessment of vascular wall damage.
Data Recording and Analysis
The primary endpoint of the studies was to determine the
efﬁcacy of the MTD for the removal of obstructing throm-
bus. This was determined by the degree of vascular recana-
lizationimmediatelyafterasinglepassofthethrombectomy
device, as well as at 15 and 30 min after the procedure. An
analysis of device safety was also conducted as a primary
endpointofthestudy.Devicesafetywasdeterminedthrough
evaluation of device failure and procedural complications.
Device failure was evaluated by ﬂuoroscopy or direct
inspection in relation to the following safety measures: (1)
solder point breakage during removal of the thrombus, (2)
unraveling or breakage of distal loops, eyelets, or proximal
loops, (3) breakage of coil bond to transition tube, and (4)
breakage of transition tube bond to hypo tube. Procedural
complications were evaluated on the basis of the following
measures: (1) vascular perforation, (2) intramural arterial
dissection, (3) embolization to previously uninvolved vas-
cular territory or territories, (4) hemorrhage in the vascular
region of interest, (5) vasospasm of the treated vessel, (6)
access site injury, (7) embolic fragmentation, and (8) distal
migration of embolic fragment or fragments.
Secondary endpoints of the study included subjective
operator evaluation of MTD performance. The following
technical and procedural data were recorded for each
device used in each study: (1) general ease of use by the
physician, (2) adequacy of device length and number of
coils, (3) ease of loading the device into the catheter, (4)
navigability to the site of embolic occlusion in a blood
vessel, (5) ease with which the device tip passed to the
distal side of the embolus, (6) ease of deployment of distal
and proximal coils, (7) ease with which distal and proximal
coils engage the embolus, (8) ease of retrieval of the
embolus from the occluded blood vessel without frag-
mentation, and (9) visibility of the device.
Results
Device Efﬁcacy
Results are summarized in Table 1. After single-pass throm-
bectomy with the MTD, retrieval of embolus from the
occlusion site achieved complete angiographically deter-
mined recanalization in 21 (81%) of 26 trials. Partial
([50%) removal of the thrombus from the occluded vessel
was demonstrated in another three vessels. Overall, partial
or complete recanalization was observed in 24 (92%) of 26
vessels treated with a single pass of the MTD.
Device Safety: Procedural Complications
There were no major complications associated with the
MTD thrombectomy procedure, including vascular perfo-
ration, intramural arterial dissection, distal embolization
from an embolic fragment, hemorrhage, or access site
injury. In initial studies with the MTD, the animals were
not pretreated with intra-arterial papaverine. Consequently,
vasospasm of the embolized blood vessel occurred in 8
(30%) of 26 vessels. This vasospasm was qualiﬁed as slight
except in one case of moderate vasospasm. Manipulations
were not strong or excessive during the procedure.
Studies indicate that porcine blood vessels are generally
very susceptible to vasospasm, and smaller caliber vessels
would be more susceptible to vasospasm even with wire
manipulations. In all instances in which vasospasm was
observed, the vasospasm resolved with intra-arterial
papaverine, without sequelae of vascular injury suggested
on subsequent angiography. In subsequent procedures in
the external carotid and smaller branch vessels, the
occluded vessel was pretreated with papaverine, which
eliminated vasospasm.
Thromboemboli fragmented during 5 of 26 procedures
that used an early version of the MTD. In one case, frag-
mentation seemed to have resulted from incomplete coil
engagement. In 4 other cases, the embolus apparently
fragmented during withdrawal from the body, when pulling
the microcatheter into the guide catheter, or out of the
access sheath. After the distal coils of the MTD were
reinforced with slightly thicker platinum, no further cases
of distal embolization were observed.
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123Histopathological analyses were performed by an inde-
pendent pathologist on three excised femoral artery vessels
treated with the MTD. The results were compared to
contralateral femoral artery segments treated with an
inﬂated Fogarty balloon. No arterial wall damage or other
vascular injury was seen with either device.
The consistency of the clot generated in this animal
model may not exactly match that of acute and chronic
human embolic/thrombotic clot. However, initial clinical
trials, now underway in human patients, suggest similar or
better results.
Device Failure
As shown in Table 1, unraveling of proximal or distal loops
during withdrawal of the embolus was observed in only
one procedure. In one test during withdrawal of an embo-
lus, the coil bond at the transition tube broke. Otherwise,
device failure was not observed during coil deployment,
thrombus capture, or during withdrawal of the obstructing
thrombus. The MTD tensile strength is greater or equal to
0.7 lb at the catheter-coil joint.
Device Adequacy and Ease of Use
Each step of the MTD operation was evaluated for ease of
use during the procedure. Overall ease of use, ease of
device loading into a standard microcatheter, and device
navigability to the site of embolic occlusion was adequate
in all trials. The device is designed to be easy to use,
allowing rapid mechanical thrombectomy requiring
approximately 4 min to load, actuate, and sweep the
occluded vessel.
The porcine iliac and subclavian arteries are quite tor-
tuous and are generally similar to human vessels with a
moderate degree of tortuosity. During bench-top evaluation
of the MTD, plastic tubing (SLA) models were constructed
on the basis of computed tomographic angiography from
patients. Acute angles encountered in peripheral and
intracranial vessels were modeled. This tubing was used in
initial pre-animal testing of the device in order to optimize
pushability, ﬂexibility, and trackability of the MTD.
The MTD was successfully deployed distal to the
embolus in all cases. The proximal and distal coils formed
in 25 (96%) of 26 vessels tested. In one vessel, the distal
and proximal coils seemed to unravel such that the embolus
could not be removed. Adequate drawing together of distal
and proximal coils by the pull string to surround the entire
embolus occurred in 23 (88%) of 26 vessels tested. In three
tests, the embolus was not completely secured by the coils
after the pull string was drawn. However, it was withdrawn
from the vessel resulting in restored patency. Adequate
tensile strength of the MTD to retrieve an embolus from the
occluded vessel was found in all cases. Adequate enme-
shing strength of distal and proximal coils to remove an
embolus without fragmentation was demonstrated in 25
cases (94%). In one trial, embolus fragmentation was
Table 1 Summary of results of preclinical studies
Outcomes measures Incidence Success
rate (%)
Device efﬁcacy parameters (single pass with device)
Retrieval of embolus from occlusion site 24/26 92
Removal of embolus from body 18/26 69
Complete vascular recanalization 21/26 81
Device utility parameters
Adequate general ease of use 26/26 100
Adequate ease of loading into standard
microcatheter
26/26 100
Adequate navigability within tortuous
vasculature
26/26 100
Adequate navigability to site of embolic
occlusion
26/26 100
Adequate deployment of device tip to distal
side of embolus
26/26 100
Adequate deployment of distal coils 25/26 96
Adequate deployment of proximal coils 25/26 96
Adequate engagement of embolus by distal
coils
25/26 96
Adequate engagement of embolus by
proximal coils
25/26 94
Adequate drawing together of distal and
proximal coils by pull string to surround
and secure embolus
23/26 88
Adequate tensile strength of device to
retrieve embolus from occlusion site
26/26 100
Adequate tensile strength of device to
remove embolus from body
26/26 100
Adequate enmeshing strength of distal and
proximal coils to remove embolus without
fragmentation
25/26 96
Device safety parameters
Procedural complications
Vascular perforation 0/26 100
Intramural arterial dissection 0/26 100
Distal embolization from embolic fragment 0/26 100
Hemorrhage 0/26 100
Vasospasm in embolized blood vessel 8/26 30
Access site injury 0/26 100
Embolic fragmentation 5/26 19
Device failure
Unraveling of distal loops 1/26 96
Unraveling of proximal loops 1/26 96
Breakage of coil bond to transition tube 1/26 96
Breakage of transition tube bond to
hypo tube
0/26 100
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123apparently caused by incomplete coil engagement, during
removal from the guide catheter and sheath.
Discussion
Vascular recanalization should be rapid, safe, and efﬁca-
cious.Currentstrategiesoftenusethrombolysisinitiallywith
subsequent use of MTDs if thrombolysis is inadequate to
recanalize the vessel [6, 7]. Thrombolysis can be a lengthy
and costly procedure with inherent risk. Thrombectomy
devices have been developed in an attempt to prolong the
therapeutic time window for stroke and to treat patients with
contra-indicationstothrombolysis[6].AMTDthatiseasyto
useandconsistentlyopensvesselscouldbecometheﬁrstline
of treatment [2]. In the current preclinical study, no throm-
bolytic agent was used.
A number of devices exist for peripheral mechanical
thrombectomy, and fewer devices exist for extra- or
intracranial thrombectomy in the setting of stroke [7–16].
For each of the devices, there are reported technical suc-
cess and complication rates [2, 3, 7, 12, 13]. The MTD is
designed to negotiate tortuous vessels and fully enmesh
and remove hard organized ﬁbrin-laden thrombus as well
as soft acute thrombus with minimal distal embolization
and without vascular injury.
The results of this study show high rates of complete
recanalization after single-pass thrombectomy with the
MTD, which compare favorably to those reported for other
MTDsusedinthesettingofstroke.RhaandSaverconducted
a meta-analysis of the stoke literature and reported vascular
recanalization rates of 83.6% with mechanical devices [17].
In the Multi-MERCI trial, the recanalization rate with the
new L5 system was 57.3% [18]. The ﬁrst Penumbra stroke
trial reported 100% recanalization with Thrombolysis in
Myocardial Infarction (TIMI) II, incomplete or partial
recanalization of the primary occlusion with distal ﬂow, of
48%, and TIMI III, complete recanalization of the primary
occlusion with distal ﬂow, in 52%, of the vessels [19]. An
81.6% recanalization rate (54.4% TIMI II and 27.2% TIMI
III) is reported in the subsequent Penumbra Pivotal Stroke
study [14]. In our pilot study, successful removal of intra-
vascular embolic/thrombotic obstruction, including soft and
hard thrombus, was demonstrated in a number of arteries,
including the external carotid artery, the subclavian and its
primary branches, and the superﬁcial femoral artery. Thus,
efﬁcacy was evaluated in arteries relevant to both stroke and
peripheral thromboembolic ischemic disease. The rate of
81% TIMI III recanalization with a single pass and no use of
a thrombolytic agent compares favorably with the best
reports in the literature to date.
The present data suggest that the MTD may have
several practical and conceptual advantages over current
commercially available mechanical retrieval systems. One
clear advantage of the proposed device is its small size and
navigability, which enable retrieval of obstructions from
small and tortuous vessels. The ability to navigate small
and tortuous vessels is clinically relevant because it is
known that many ischemic strokes are a result of the
occlusion of intracranial arteries, such as the middle cere-
bral artery or its branches, or the basilar artery or its
branches [4, 8]. In peripheral arterial thromboembolic
disease, removal of thrombus from the small caliber pop-
liteal and or tibial branches is essential and often entails
navigation of tortuous vessels such as the iliac arteries
when contralateral access is used.
It has been reported that current peripheral arterial
thrombectomy devices have a 2–18% rate of distal embo-
lization [2, 12]. In vitro ﬂow studies have been used to
compare distal embolization rates of a number of com-
monly used rheolytic and MTDs [13]. Initial clinical trials
evaluating the Trellis device (Bacchus Vascular, Santa
Clara, CA) suggested an 11% incidence of distal emboli-
zation [16]. The design of the MTD described here may
explain the absence of distal embolization during clot
removal. The MTD is essentially a series of coils that are
placed around the thrombus to cocoon it and then pulled
tightly with a pull wire. The coil envelope keeps the
thrombus from fragmenting during withdrawal [9]. This
may provide a distinct advantage over other MTDs.
Angiographic visualization during the present throm-
bectomy studies indicated that there was no distal macro-
embolization, although in 4 of 26 cases there was shearing
and fragmentation of thrombus from the device when
removing the clot burden from the valved 10F vascular
sheath. Clot could be purged from the sheath after use of
the MTD, if removed over a wire. No distal embolization at
the site of clot retrieval is observed angiographically. The
clot burden removed from these vessels is thought to
greatly exceed that removed during stroke thrombectomy.
Strategies for more complete clot removal from the MTD
sheath include a valveless vascular sheath and a ﬂared,
cinchable sheath for clot capture, both of which are cur-
rently being developed and optimized. Studies of the MTD
using a pulsatile ﬂow model, similar to that described by
Mu ¨ller-Hu ¨lsbeck et al. [13], have demonstrated that no
clinically signiﬁcant fragmentation of emboli are generated
during MTD removal of blood clots. Device failure with
MTD procedures was rarely encountered and most com-
monly resulted from unraveling of the coil complex and
inadequate ﬁrst-pass retrieval of the intact thrombus. All
operators’ subjective measures of ease of use and most
measures of adequacy were favorable.
The occurrence of hemolysis, with resultant adenosine
release and possible bradycardia, has been reported in
6–14% cases when rheolytic thrombectomy devices are
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123used [12]. Ultrasound-assisted thrombolytic approaches
also have associated hemolysis, although at a lower level
than with the AngioJet device [15]. By comparison,
hemolysis is unlikely with the MTD because no maceration
of blood constituents occurs during thrombectomy.
Traumatic adverse events, including hemorrhage in
6–10% cases, dissection in 6–8% cases, and vessel perfo-
ration in 4% cases, have been reported for a number of
current MTDs [12]. In contrast, no vascular injury was
demonstrated angiographically or by histopathologic eval-
uation after use of the MTD in the present study. This is
likely because the MTD uses soft and nontraumatic coils to
mechanically retract blood clots. The MTD coils have an
adjustable stiffness that provides reliable dynamic com-
pliance matching the viscoelastic properties of the
obstructing thrombus being retrieved, thereby facilitating
control of gripping forces on the obstruction while reduc-
ing circumferential contact of the device with the blood
vessel endoluminal surfaces.
A ﬁnal notable attribute of the MTD is that the throm-
bectomy procedure time is approximately 2 to 6 min,
without extensive preparation time as with other throm-
bectomy devices. Furthermore, because a thrombolytic
agent is not required, there is no lost time, as when a ‘‘lyse
and wait’’ or other thrombolytic infusion strategies are
used. All operators’ subjective measures of ease of use and
most measures of adequacy were favorable with the MTD.
In conclusion, the MTD is intended to remove both soft
acute blood clot and hard, organized embolic/thrombotic
obstructions. These initial porcine studies demonstrate that
the MTD is safe, effective, and easy to use. The design of
the MTD allows it to be easily modiﬁed and optimized for
mechanical thrombectomy procedures in any vascular ter-
ritory. The preliminary animal- study data reported here
also indicate that this device may be useful in several
clinical settings, including acute stroke, dialysis graft/ﬁs-
tula salvage, deep venous thrombosis, peripheral throm-
botic/embolic arterial occlusion, pulmonary embolism
thrombectomy, and coronary artery thrombotic/embolic
occlusion. Clinical trials with the MTD thrombectomy
device are now underway.
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